<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098981</url>
  </required_header>
  <id_info>
    <org_study_id>CEREVAST THERAPEUTICS CP-01</org_study_id>
    <nct_id>NCT01098981</nct_id>
  </id_info>
  <brief_title>Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke</brief_title>
  <acronym>CLOTBUST-ER</acronym>
  <official_title>A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerevast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerevast Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, phase 3 clinical trial to evaluate the efficacy and&#xD;
      safety of transcranial ultrasound (US) as an adjunctive therapy to tissue plasminogen&#xD;
      activator (tPA) treatment in subjects with acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is to provide information regarding the efficacy of a&#xD;
      combined treatment with transcranial US and systemic tPA (Target group) compared to systemic&#xD;
      tPA alone (Control group) in subjects with acute ischemic stroke. The primary efficacy&#xD;
      endpoint is functional outcome at 3 months from stroke onset (modified Rankin Score ordinal&#xD;
      shift analysis). The primary safety endpoint is the proportion of subjects in the Target vs&#xD;
      Control group experiencing symptomatic intracranial hemorrhage (sICH) within 24 hours of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin score ordinal shift analysis</measure>
    <time_frame>3 months</time_frame>
    <description>The primary objective of this study is to compare clinical recovery rates (modified Rankin score ordinal shift analysis) at 3 months after stroke onset.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracerebral hemorrhage</measure>
    <time_frame>0-24 hours from treatment</time_frame>
    <description>The secondary outcome is a comparison of the rates of symptomatic intracerebral hemorrhage within 0-24 hours from initiation of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">675</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Target group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combined treatment with transcranial US and systemic tPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systemic tPA alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial ultrasound as an adjunctive therapy to tPA</intervention_name>
    <description>tPA per approved labeling administered over 60 minutes&#xD;
Ultrasonic headframe with active insonation for 120 minutes</description>
    <arm_group_label>Target group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care tPA therapy for acute ischemic stroke</intervention_name>
    <description>tPA per approved labeling administered over 60 minutes&#xD;
Ultrasonic headframe with sham (inactive) insonation for 120 minutes</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females 18 - 80 years of age&#xD;
&#xD;
          2. Subjects presenting within timeframe for intravenous tPA treatment approved by local&#xD;
             regulatory authorities but no more than 4.5 hours from onset of symptoms&#xD;
&#xD;
          3. No signs of intracranial bleeding on assessment by non-contrast CT&#xD;
&#xD;
          4. Subjects with neurological deficits of a total NIHSS score ≥ 10 points&#xD;
&#xD;
          5. Subjects that in the opinion of the treating physician require treatment with full&#xD;
             dose IV tPA as standard of care per institutional standards&#xD;
&#xD;
          6. SBP &lt; 185 mmHg and DBP &lt; 105 mmHg at baseline or after treatment of hypertension with&#xD;
             medications prior to tPA bolus&#xD;
&#xD;
          7. Pre-morbid modified Rankin score of 0-1&#xD;
&#xD;
          8. Provision of informed consent as demonstrated by the subject's signature or by the&#xD;
             signature of the subject's authorized legal representative on the Informed Consent&#xD;
             Form in accordance with all local and national regulations&#xD;
&#xD;
          9. Co-signature on the Informed Consent Form by a qualified member of the study staff&#xD;
             signifying that, in his/her professional opinion, informed consent has been obtained&#xD;
             in accordance with all local and national regulations&#xD;
&#xD;
         10. For subjects in the optional arterial recanalization substudy:&#xD;
&#xD;
               1. Occlusion located in the intracranial carotid tee through mid M2 or proximal A2,&#xD;
                  or intracranial vertebrobasilar or P1/proximal P2 segments or tandem lesions&#xD;
&#xD;
               2. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min for patients undergoing&#xD;
                  CTA or MRA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with primary intra-arterial thrombolysis&#xD;
&#xD;
          2. Females who are pregnant or breast feeding&#xD;
&#xD;
          3. Subjects receiving other investigational drugs, procedures, or therapies within 30&#xD;
             days prior to study treatment&#xD;
&#xD;
          4. Subjects with any standard contraindication for intravenous tPA therapy&#xD;
&#xD;
          5. Significant concurrent medical/neurological conditions or test values that, in the&#xD;
             opinion of the investigator, pose significant risk to the subject and warrant&#xD;
             exclusion from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cerevast Therapeutics, Inc.</name>
      <address>
        <city>Redmond</city>
        <state>Washington</state>
        <zip>98052-2431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 2, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <last_update_submitted>April 3, 2015</last_update_submitted>
  <last_update_submitted_qc>April 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

